Are you treating breast cancer patients with Avastin? If so, how?

Article

Many doctors are currently struggling with how to use Avastin to treat their breast cancer patients after the recent FDA ruling. If you are currently using Avastin to treat breast cancer patients, please share your thoughts on treatment options and combinations here.

Many doctors are currently struggling with how to use Avastin to treat their breast cancer patients after the recent FDA ruling. If you are currently using Avastin to treat breast cancer patients, please share your thoughts on treatment options and combinations here.

Are you still treating breast cancer patients with Avastin? And if so, how?

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
2 experts in this video
2 experts in this video
2 experts are featured in this series.
2 experts are featured in this series.
Related Content
Neoadjuvant Endocrine Therapy Could Sway Breast Cancer Radiation Paradigms

Neoadjuvant Endocrine Therapy Could Sway Breast Cancer Radiation Paradigms

Ariana Pelosci
May 1st 2025
Article

Ninety days of endocrine therapy before surgery could change patient/surgeon preference on concurrent radiation use in those with breast cancer.

Beyond Surgery: The Evolving Landscape of Adjuvant Therapy in Kidney Cancer

Beyond Surgery: The Evolving Landscape of Adjuvant Therapy in Kidney Cancer

Manojkumar Bupathi, MD, MS;Manojkumar Bupathi, MD, MS
May 1st 2025
Podcast

Oncology Decoded hosts discuss adjuvant therapy in kidney cancer, including research, treatment strategies, and management of recurrence.

KN026/Chemo Meets PFS End Point in HER2+ Gastric Cancer in 2L Setting

KN026/Chemo Meets PFS End Point in HER2+ Gastric Cancer in 2L Setting

Tim Cortese
May 1st 2025
Article

Results from the phase 2/3 trial also show a favorable OS trend for KN026 with chemotherapy vs placebo with chemotherapy in HER2-positive gastric cancer.

A dedicated, well-trained, and expert staff at the Ivy Brain Tumor Center enables the facility to be at the forefront of cutting-edge radiosurgery treatment.

Elucidating Non-Invasive Radiosurgery Advancements in CNS Tumors

William R. Kennedy, MD
April 28th 2025
Podcast

A dedicated, well-trained, and expert staff at the Ivy Brain Tumor Center enables the facility to be at the forefront of cutting-edge radiosurgery treatment.

Sotorasib at 960 mg Plus Panitumumab Emerges as SOC in KRAS G12C+ mCRC

Sotorasib at 960 mg Plus Panitumumab Emerges as SOC in KRAS G12C+ mCRC

Tim Cortese
May 1st 2025
Article

Results from the phase 3 CodeBreaK trial support the use of 960 mg of sotorasib plus panitumumab as standard of care in metastatic colorectal cancer.

Event-free survival events were observed in 37.5% of patients taking pembrolizumab vs 45.3% without among patients with resectable locally advanced HNSCC.

Perioperative Pembrolizumab Enhances Survival in Locally Advanced HNSCC

Ashley Chan
April 30th 2025
Article

Event-free survival events were observed in 37.5% of patients with resectable locally advanced HNSCC who took pembrolizumab vs 45.3% in those who did not.